Zynerba Pharmaceuticals (NASDAQ:ZYNE)‘s stock had its “buy” rating reaffirmed by research analysts at LADENBURG THALM/SH SH in a research note issued on Thursday, May 30th, AnalystRatings.com reports. They currently have a $26.00 target price on the stock. LADENBURG THALM/SH SH’s price target suggests a potential upside of 134.87% from the stock’s current price.
Several other brokerages also recently issued reports on ZYNE. ValuEngine downgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Roth Capital started coverage on shares of Zynerba Pharmaceuticals in a research note on Tuesday, April 30th. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $11.00 price target on shares of Zynerba Pharmaceuticals in a research note on Thursday, March 7th. Zacks